Search

Your search keyword '"Gobbi, C"' showing total 557 results
Start Over Author "Gobbi, C"
557 results on '"Gobbi, C"'

1. AB0068 LONG-TERM FOLLOW-UP OF PATIENTS WITH RHEUMATIC DISEASES AND SARS-CoV-2 INFECTION: DATA FROM THE SAR-COVID REGISTRY

Author

Isnardi, C. A., primary, Alfaro, M. A., additional, Virasoro, B. M., additional, Gómez, G., additional, D´angelo, M. E., additional, Saurit, V., additional, Petkovic, I. E., additional, Quintana, R., additional, Tissera, Y., additional, Pisoni, C., additional, Berbotto, G., additional, Haye Salinas, M., additional, Ornella, S., additional, Pera, M., additional, Reyes, A. A., additional, Baez, R., additional, Pereira, D. A., additional, Alle, G., additional, Castro Coello, V. V., additional, Alba, P., additional, Cogo, A. K., additional, Alonso, C. G., additional, Gobbi, C., additional, Gallino Yanzi, J., additional, and Pons-Estel, G., additional

Published
2024
Full Text
View/download PDF

2. POS1016 THE IMPACT OF ACTIVE LUPUS NEPHRITIS ON WORK PRODUCTIVITY IN PATIENTS FROM A LATIN AMERICAN LUPUS COHORT

Author

Pons-Estel, G., primary, Nieto, R., additional, Quintana, R., additional, Fernández Ávila, D. C., additional, Serrano, R., additional, Harvey, G., additional, Hernández, L., additional, Roberts, K., additional, Catoggio, L., additional, Subils, G., additional, Gobbi, C., additional, Bordon, F., additional, Ibañez Peña, P. D., additional, Berbotto, L. A., additional, Bertolaccini, M. C., additional, Rinesi, D. O., additional, De Los Ángeles Gargiulo, M., additional, Pisoni, C., additional, Serventi, J. M., additional, Buschiazzo, E., additional, Barbosa, V., additional, Monticielo, O. A., additional, Albanez de A. Da C. Andrade, C., additional, Machado Ribeiro, F., additional, Bonfa, E., additional, Borba, E. F., additional, Sato, E. I., additional, Bondi, A. P., additional, Donoso, S., additional, Aroca Martínez, G., additional, Medina, H., additional, Echeverri, A., additional, Molina-Rios, S., additional, Rubio Rivera, M., additional, Lopez Martinez, R., additional, Moreno Alvarez, M., additional, Vera Lastra, O. L., additional, Pérez Cristóbal, M., additional, Núñez Álvarez, C., additional, Amezcua-Guerra, L. M., additional, García-Valladares, I., additional, Abud Mendoza, C., additional, Galarza-Delgado, D. A., additional, Vázquez, M., additional, Paats, A., additional, Cieza Calderón, J. N., additional, Quiros Alva, A. M., additional, Muñoz Louis, R., additional, Pizzarossa, C., additional, Carlomango, A., additional, Gamboa-Cardenas, R. V., additional, Alarcón, G. S., additional, Sbarigia, U., additional, Zazzetti, F., additional, Orillion, A., additional, and Pons-Estel, B., additional

Published
2024
Full Text
View/download PDF

3. AB1046 EVALUATION OF ACCRUAL DAMAGE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: COMPARISON OF DATA FROM THE NATIONAL CROSS-SECTIONAL AND PROSPECTIVE LUPUS REGISTRY

Author

Dapeña, J. M., primary, Garcia, L., additional, Gobbi, C., additional, Quintana, R., additional, Alba, P., additional, Roverano, S., additional, Alvarez, A., additional, Graff, C., additional, Pisoni, C., additional, Spindler, A., additional, Gomez, C., additional, Figueredo, H. M., additional, Papasidero, S., additional, Paniego, R. H., additional, De la Vega, M. C., additional, Civit, E. E., additional, González Lucero, L., additional, Martire, M. V., additional, Águila Maldonado, R., additional, Gordon Dolimpio, S. A., additional, Micelli, M. L., additional, Nieto, R., additional, Rausch, G., additional, Góngora, V., additional, D´amico, M. A., additional, Dubinsky, D., additional, Orden, A. O., additional, Zacariaz, J., additional, Romero, J., additional, Pera, M., additional, Goñi, M. A., additional, Rillo, O., additional, Baez, R., additional, Arturi, V., additional, Gonzalez, A., additional, Vivero, F., additional, Bedoya, M. E., additional, Schmid, M., additional, Caputo, V., additional, Larroude, M. S., additional, Dominguez, N., additional, Gomez, G., additional, Rodriguez, G., additional, Marin, J., additional, Collado, M. V., additional, Jorfen, M., additional, Bedran, Z., additional, Curti, A., additional, Gazzoni, M. V., additional, Sarano, J., additional, Finucci, P., additional, Rojas Tessel, R., additional, Arias Saavedra, M., additional, Sattler, M. E., additional, Machado Escobar, M., additional, Astesana, P., additional, Paris, U. V., additional, Vandale, J. M., additional, Santa Cruz, M. J., additional, Pons-Estel, B., additional, Corbalán, P. M., additional, Mendoza Martinez, L. M., additional, Alle, G., additional, Sardi, B., additional, Sarde, M., additional, Gordillo, M. F., additional, Pons-Estel, G., additional, and García, M. A., additional

Published
2024
Full Text
View/download PDF

4. Sleep-Related Breathing Disorders in Multiple Sclerosis: Prevalence, Features and Associated Factors

Author

Sparasci D, Fanfulla F, Ferri R, Aricò D, Distefano D, Pravatà E, Heinzer R, Haba-Rubio J, Berger M, Riccitelli GC, Gobbi C, Zecca C, and Manconi M

Subjects
sleep-related breathing disorders, multiple sclerosis, sleep quality, polysomnography, Psychiatry, RC435-571, Neurophysiology and neuropsychology, QP351-495
Abstract

Davide Sparasci,1 Francesco Fanfulla,2 Raffaele Ferri,3 Debora Aricò,3 Daniela Distefano,4 Emanuele Pravatà,4 Raphael Heinzer,5 José Haba-Rubio,5 Mathieu Berger,5 Gianna Carla Riccitelli,6– 8 Claudio Gobbi,6,8 Chiara Zecca,6,8,* Mauro Manconi1,8,* 1Sleep Medicine Unit, Neurocenter of Southern Switzerland, Lugano, Switzerland; 2Sleep Medicine Unit, Istituti Clinici Scientifici Maugeri, IRCCS, Scientific Institute of Pavia, Pavia, Italy; 3Sleep Research Centre; Department of Neurology I.C., Oasi Institute for Research on Mental Retardation and Brain Aging (IRCCS), Troina, Italy; 4Neuroradiology Clinic, Ospedale Regionale di Lugano, Neurocenter of Southern Switzerland, Lugano, Switzerland; 5Center for Investigation and Research in Sleep (CIRS), Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland; 6Multiple Sclerosis Center, Neurocenter of Southern Switzerland, Lugano, Switzerland; 7Neuropsychology and Behavioural Neurology Research Unit, Neurocenter of Southern Switzerland, Lugano, Switzerland; 8Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland*These authors contributed equally to this workCorrespondence: Raffaele Ferri, Sleep Research Centre; Department of Neurology I.C., Oasi Institute for Research on Mental Retardation and Brain Aging (IRCCS), Via Conte Ruggero 73, Troina, 94018, Italy, Email rferri@oasi.en.itBackground: Multiple sclerosis (MS) represents a risk factor for sleep disorders, but there are conflicting results about the prevalence and severity of sleep-related breathing disorders (SRBD) in MS. Most available data come from self-administered questionnaires.Objective: To conduct a polysomnographic study in MS focused on SRBD, compared to a group of healthy controls (HC), also considering the neuroimaging findings. To evaluate the impact of SRBD on vigilance, fatigue and depression in MS.Methods: In this cross-sectional, observational, instrumental study, 67 MS patients (men/women: 20/47; mean age: 50.6± 8.2 years) underwent PSG and maintenance of wakefulness test. Findings were compared to 67 age-, sex-, BMI-matched HC, by using parametric (Student’s t-test) and nonparametric statistics (chi-squared test). A subgroup analysis was then performed, evaluating the influence of brainstem (mesencephalic, pontine and medullary) lesions at neuroimaging on instrumental and clinical data: MS patients with at least one brainstem lesion vs MS patients without vs HC.Results: The frequency of SRBD was comparable in MS patients and HC. No MS patient had a central apnea index ≥ 2/h. The respiratory disturbance index (RDI) did not correlate to clinical parameters such as fatigue and depression. Patients with MS were drowsier than HC (47% vs 26%, p = 0.019) and showed a worse sleep pattern, in terms of duration, efficiency and architecture.Conclusion: Our study does not provide evidence of an association between MS-specific symptoms such as fatigue, sleepiness, depression and central or obstructive apneas, even in the presence of brainstem lesions.Keywords: sleep-related breathing disorders, multiple sclerosis, sleep quality, polysomnography

Published
2022

5. Congenital heart disease in the ESC EORP Registry of Pregnancy and Cardiac disease (ROPAC)

Author

Hall, Roger, Roos-Hesselink, Jolien, Stein, Joerg, Parsonage, William Anthony, Budts, Werner, De Backer, Julie, Grewal, Jasmin, Marelli, Ariane, Kaemmerer, Harald, Jondeau, Guillaume, Johnson, Mark, Maggioni, Aldo P., Tavazzi, Luigi, Thilen, Ulf, Elkayam, Uri, Otto, Catherine, Sliwa, Karen, Aquieri, A., Saad, A., Vega, H. Ruda, Hojman, J., Caparros, J.M., Blanco, M. Vazquez, Arstall, M., Chung, C.M., Mahadavan, G., Aldridge, E., Wittwer, M., Chow, Y.Y., Parsonage, W.A., Lust, K., Collins, N., Warner, G., Hatton, R., Gordon, A., Nyman, E., Stein, J., Donhauser, E., Gabriel, H., Bahshaliyev, A., Guliyev, F., Hasanova, I., Jahangirov, T., Gasimov, Z., Salim, A., Ahmed, C.M., Begum, F., Hoque, M.H., Mahmood, M., Islam, M.N., Haque, P.P., Banerjee, S.K., Parveen, T., Morissens, M., De Backer, J., Demulier, L., de Hosson, M., Budts, W., Beckx, M., Kozic, M., Lovric, M., Kovacevic-Preradovic, T., Chilingirova, N., Kratunkov, P., Wahab, N., McLean, S., Gordon, E., Walter, L., Marelli, A., Montesclaros, A.R., Monsalve, G., Rodriguez, C., Balthazar, F., Quintero, V., Palacio, W., Cadavid, L.A. Mejía, Ortiz, E. Munoz, Hoyos, F. Fortich, Guerrero, E. Arevalo, Ricardo, J. Gandara, Penagos, J. Velasquez, Vavera, Z., Prague, Popelova, J., Vejlstrup, N., Grønbeck, L., Johansen, M., Ersboll, A., Elrakshy, Y., Eltamawy, K., Abd-El Aziz, M. Gamal, El Nagar, A., Ebaid, H., Elenin, H. Abo, Saed, M., Farag, S., Makled, W., Sorour, K., Ashour, Z., El-Sayed, G., Meguid Mahdy, M. Abdel, Taha, N., Dardeer, A., Shabaan, M., Ali, M., Moceri, P., Duthoit, G., Gouton, M., Nizard, J., Baris, L., Cohen, S., Ladouceur, M., Khimoud, D., Iung, B., Berger, F., Olsson, A., Gembruch, U., Merz, W.M., Reinert, E., Clade, S., Kliesch, Y., Wald, C., Sinning, C., Kozlik-Feldmann, R., Blankenberg, S., Zengin-Sahm, E., Mueller, G., Hillebrand, M., Hauck, P., von Kodolitsch, Y., Zarniko, N., Baumgartner, Muenster H., Schmidt, R., Hellige, A., Tutarel, O., Kaemmerer, H., Kuschel, B., Nagdyman, N., Motz, R., Maisuradze, D., Frogoudaki, A., Iliodromitis, E., Anastasiou-Nana, M., Marousi, Triantafyllis, D., Bekiaris, G., Karvounis, H., Giannakoulas, G., Ntiloudi, D., Mouratoglou, S.A., Temesvari, A., Balint, H., Kohalmi, D., Merkely, B., Liptai, C., Nemes, A., Forster, T., Kalapos, A., Berek, K., Havasi, K., Ambrus, N., Shelke, A., Kawade, R., Patil, S., Martanto, E., Aprami, T.M., Purnomowati, A., Cool, C.J., Hasan, M., Akbar, R., Hidayat, S., Dewi, T.I., Permadi, W., Soedarsono, D.A., Ansari-Ramandi, M.M., Samiei, N., Tabib, A., Kashfi, F., Ansari-Ramandi, S., Rezaei, S., Farhan, H. Ali, Al-Hussein, A., Al-Saedi, G., Mahmood, G., Yaseen, I.F., Al-Yousuf, L., AlBayati, M., Mahmood, S., Raheem, S., AlHaidari, T., Dakhil, Z., Thornton, P., Donnelly, J., Bowen, M., Blatt, A., Elbaz-Greener, G., Shotan, A., Yalonetsky, S., Goland, S., Biener, M., Assenza, G. Egidy, Bonvicini, M., Donti, A., Bulgarelli, A., Prandstraller, D., Romeo, C., Crepaz, R., Sciatti, E., Metra, M., Orabona, R., Ali, L. Ait, Festa, P., Fesslova, V., Bonanomi, C., Calcagnino, M., Lombardi, F., Colli, A.M., Ossola, M.W., Gobbi, C., Gherbesi, E., Tondi, L., Schiavone, M., Squillace, M., Carmina, M.G., Maina, A., Macchi, C., Gollo, E., Comoglio, F.M., Montali, N., Re, P., Bordese, R., Todros, T., Donvito, V., Marra, W. Grosso, Sinagra, G., D'Agata Mottolese, B., Bobbo, M., Gesuete, V., Rakar, S., Ramani, F., Niwa, K., Mekebekova, D., Mussagaliyeva, A., Lee, T., Mirrakhimov, E., Abilova, S., Bektasheva, E., Neronova, K., Lunegova, O., Žaliūnas, R., Jonkaitienė, R., Petrauskaitė, J., Laucevicius, A., Jancauskaite, D., Lauciuviene, L., Gumbiene, L., Lankutiene, L., Glaveckaite, S., Laukyte, M., Solovjova, S., Rudiene, V., Chee, K.H., Yim, C.C.-W., Ang, H.L., Kuppusamy, R., Watson, T., Caruana, M., Estensen, M.-E., Kayani, M.G.A. Mahmood, Munir, R., Tomaszuk-Kazberuk, A., Sobkowicz, B., Przepiesc, J., Lesniak-Sobelga, A., Tomkiewicz-Pajak, L., Komar, M., Olszowska, M., Podolec, P., Wisniowska-Smialek, S., Lelonek, M., Faflik, U., Cichocka-Radwan, A., Plaskota, K., Trojnarska, O., Guerra, N., de Sousa, L., Cruz, C., Ribeiro, V., Jovanova, S., Petrescu, V., Jurcut, R., Ginghina, C., Coman, I. Mircea, Musteata, M., Osipova, O., Golivets, T., Khamnagadaev, I., Golovchenko, O., Nagibina, A., Ropatko, I., Gaisin, I.R., Shilina, L. Valeryevna, Sharashkina, N., Shlyakhto, E., Irtyuga, O., Moiseeva, O., Karelkina, E., Zazerskaya, I., Kozlenok, A., Sukhova, I., Jovovic, L., Prokšelj, K., Koželj, M., Askar, A.O., Abdilaahi, A.A., Mohamed, M.H., Dirir, A.M., Sliwa, K., Manga, P., Pijuan-Domenech, A., Galian-Gay, L., Tornos, P., Subirana, M.T., T, M., Subirana, Oliver, J.M., Garcia-Aranda Dominguez, B., Gonzalez, I. Hernandez, Jimenez, J.F. Delgado, Subias, P. Escribano, Murga, N., Elbushi, A., Suliman, A., Jazzar, K., Murtada, M., Ahamed, N., Dellborg, M., Furenas, E., Jinesjo, M., Skoglund, K., Eriksson, P., Gilljam, T., Thilen, U., Tobler, D., Wustmann, K., Schwitz, F., Schwerzmann, M., Rutz, T., Bouchardy, J., Greutmann, M., Lopes, B.M. Santos, Meier, L., Arrigo, M., de Boer, K., Konings, T., Wajon, E., Wagenaar, L.J., Polak, P., Pieper, E.P.G., Roos-Hesselink, J., van Hagen, I., Duvekot, H., Cornette, J.M.J., De Groot, C., van Oppen, C., Sarac, L., Esen, O. Batukan, Enar, S. Catirli, Mondo, C., Ingabire, P., Nalwanga, B., Semu, T., Salih, B.T., Almahmeed, W.A.R., Wani, S., Farook, F.S. Mohamed, Ain, Al, Gerges, F., Komaranchath, A.M., Al bakshi, F., Al Mulla, A., Yusufali, A.H., Al Hatou, E.I., Bazargani, N., Hussain, F., Hudsmith, L., Thompson, P., Thorne, S., Bowater, S., Money-Kyrle, A., Clifford, P., Ramrakha, P., Firoozan, S., Chaplin, J., Bowers, N., Adamson, D., Schroeder, F., Wendler, R., Hammond, S., Nihoyannopoulos, P., Norfolk, Norwich, Hall, R., Freeman, L., Veldtman, G., Kerr, J., Tellett, L., Scott, N., Bhatt, A.B., DeFaria Yeh, D., Youniss, M.A., Wood, M., Sarma, A.A., Tsiaras, S., Stefanescu, A., Duran, J.M., Stone, L., Majdalany, D.S., Chapa, J., Chintala, K., Gupta, P., Botti, J., Ting, J., Davidson, W.R., Wells, G., Sparks, D., Paruchuri, V., Marzo, K., Patel, D., Wagner, W., Ahanya, S.N., Colicchia, L., Jentink, T., Han, K., Loichinger, M., Parker, M., Longtin, C., Yetman, A., Erickson, K., Cramer, J., Tsai, S., Fletcher, B., Warta, S., Cohen, C., Lindblade, C., Puntel, R., Nagaran, K., Croft, N., Gurvitz, M., Otto, C., Talluto, C., Murphy, D., Perlroth, M.G., Ramlakhan, Karishma P., Johnson, Mark R., Lelonek, Malgorzata, Saad, Aly, Gasimov, Zaur, Sharashkina, Natalia V., Thornton, Patrick, Arstall, Margaret, and Roos-Hesselink, Jolien W.

Published
2021
Full Text
View/download PDF

7. Phase I clinical trial of intracerebroventricular transplantation of allogeneic neural stem cells in people with progressive multiple sclerosis

Author

Leone, M, Gelati, M, Profico, D, Gobbi, C, Pravata, E, Copetti, M, Conti, C, Abate, L, Amoruso, L, Apollo, F, Balzano, R, Bicchi, I, Carella, M, Ciampini, A, Colosimo, C, Crociani, P, D'Aloisio, G, Di Viesti, P, Ferrari, D, Fogli, D, Fontana, A, Frondizi, D, Grespi, V, Kuhle, J, Laborante, A, Lombardi, I, Muzi, G, Paci, F, Placentino, G, Popolizio, T, Ricciolini, C, Sabatini, S, Silveri, G, Spera, C, Stephenson, D, Stipa, G, Tinella, E, Zarrelli, M, Zecca, C, Ventura, Y, D'Alessandro, A, Peruzzotti-Jametti, L, Pluchino, S, Vescovi, A, Leone M. A., Gelati M., Profico D. C., Gobbi C., Pravata E., Copetti M., Conti C., Abate L., Amoruso L., Apollo F., Balzano R. F., Bicchi I., Carella M., Ciampini A., Colosimo C., Crociani P., D'Aloisio G., Di Viesti P., Ferrari D., Fogli D., Fontana A., Frondizi D., Grespi V., Kuhle J., Laborante A., Lombardi I., Muzi G., Paci F., Placentino G., Popolizio T., Ricciolini C., Sabatini S., Silveri G., Spera C., Stephenson D., Stipa G., Tinella E., Zarrelli M., Zecca C., Ventura Y., D'Alessandro A., Peruzzotti-Jametti L., Pluchino S., Vescovi A. L., Leone, M, Gelati, M, Profico, D, Gobbi, C, Pravata, E, Copetti, M, Conti, C, Abate, L, Amoruso, L, Apollo, F, Balzano, R, Bicchi, I, Carella, M, Ciampini, A, Colosimo, C, Crociani, P, D'Aloisio, G, Di Viesti, P, Ferrari, D, Fogli, D, Fontana, A, Frondizi, D, Grespi, V, Kuhle, J, Laborante, A, Lombardi, I, Muzi, G, Paci, F, Placentino, G, Popolizio, T, Ricciolini, C, Sabatini, S, Silveri, G, Spera, C, Stephenson, D, Stipa, G, Tinella, E, Zarrelli, M, Zecca, C, Ventura, Y, D'Alessandro, A, Peruzzotti-Jametti, L, Pluchino, S, Vescovi, A, Leone M. A., Gelati M., Profico D. C., Gobbi C., Pravata E., Copetti M., Conti C., Abate L., Amoruso L., Apollo F., Balzano R. F., Bicchi I., Carella M., Ciampini A., Colosimo C., Crociani P., D'Aloisio G., Di Viesti P., Ferrari D., Fogli D., Fontana A., Frondizi D., Grespi V., Kuhle J., Laborante A., Lombardi I., Muzi G., Paci F., Placentino G., Popolizio T., Ricciolini C., Sabatini S., Silveri G., Spera C., Stephenson D., Stipa G., Tinella E., Zarrelli M., Zecca C., Ventura Y., D'Alessandro A., Peruzzotti-Jametti L., Pluchino S., and Vescovi A. L.

Abstract

We report the analysis of 1 year of data from the first cohort of 15 patients enrolled in an open-label, first-in-human, dose-escalation phase I study (ClinicalTrials.gov: NCT03282760, EudraCT2015-004855-37) to determine the feasibility, safety, and tolerability of the transplantation of allogeneic human neural stem/progenitor cells (hNSCs) for the treatment of secondary progressive multiple sclerosis. Participants were treated with hNSCs delivered via intracerebroventricular injection in combination with an immunosuppressive regimen. No treatment-related deaths nor serious adverse events (AEs) were observed. All participants displayed stability of clinical and laboratory outcomes, as well as lesion load and brain activity (MRI), compared with the study entry. Longitudinal metabolomics and lipidomics of biological fluids identified time- and dose-dependent responses with increased levels of acyl-carnitines and fatty acids in the cerebrospinal fluid (CSF). The absence of AEs and the stability of functional and structural outcomes are reassuring and represent a milestone for the safe translation of stem cells into regenerative medicines.

Published
2023

8. HYPERON RADIATIVE DECAYS IN THE BOUND STATE SOLITON MODEL

Author

Schat, C. L., Gobbi, C., and Scoccola, N. N.

Subjects
High Energy Physics - Phenomenology
Abstract

The radiative decays of hyperons are studied in the framework of the bound state soliton model. Detailed predictions for the total decay widths and the E2/M1 ratios corresponding to decuplet--to--octet electromagnetic transitions are presented in relation to future planned experiments at CEBAF and Fermilab. The results are compared to those obtained in quark based models., Comment: 9 pages, Latex

Published
1995
Full Text
View/download PDF

10. Lambda(1405) in the Bound State Soliton Model

Author

Schat, C. L., Scoccola, N. N., and Gobbi, C.

Subjects
High Energy Physics - Phenomenology
Abstract

The strong and electromagnetic properties of the Lambda(1405) hyperon are studied in the framework of the bound state soliton model. We explicitly evaluate the strong coupling constant g(Lambda^*-N-K), the Lambda^* magnetic moment, mean square radii and radiative decay amplitudes. The results are shown to be in general agreement with available empirical data. A comparison with results of other models is also presented., Comment: 15 pages (Latex), preprint TAN-FNT-94-09

Published
1994
Full Text
View/download PDF

11. Strong Decays of $Q \bar Q$ Mesons

Author

Gobbi, C., Iachello, F., and Kusnezov, D.

Subjects
High Energy Physics - Phenomenology
Abstract

We present a detailed study of the two-body strong decays of light mesons. Both the space part and the spin-flavor-color part of the wave functions are generated algebraically and closed forms are obtained for all decays. Experimental deviations from our systematics are seen to be suggestive of both missing mesons and exotic QCD configurations., Comment: 24 pages (+6 figures, available from the authors), LATEX file, Yale preprint YCTP-N18-93

Published
1993
Full Text
View/download PDF

12. Bound State Soliton Description of Low Partial Wave Octet Baryon Resonances

Author

Gobbi, C. and Scoccola, N. N.

Subjects
High Energy Physics - Phenomenology
Abstract

A version of the bound state soliton model which allows both $\eta$ and $K$ bound states is used to study low partial wave octet baryon resonances. It is found that negative parity $S-$wave resonances are well described within this framework. A possible interpretation of the $P-$wave resonances is also discussed., Comment: 8 pages (+ 2 figures, available from the authors), Latex file, TAN-FNT-93-08

Published
1993
Full Text
View/download PDF

13. POS0974 CARDIOVASCULAR OUTCOMES OF ANTI-TNF ALFA AND JAK INHIBITORS IN PATIENTS WITH RHEUMATOID AND PSORIATIC ARTHRITIS. REAL WORLD EVIDENCE AND INSIGHTS OF BIOBADASAR 3.0 REGISTRY

Author

Brigante, J. A., primary, Roberts, K., additional, Isnardi, C. A., additional, Gómez, G., additional, Holguín Arias, L. L., additional, Pons-Estel, B., additional, Gamba, J., additional, Haye, M., additional, Dapeña, J. M., additional, Secco, A., additional, Savio, V., additional, Soliz Cordero, C., additional, Gobbi, C., additional, Velozo, E., additional, Catay, E., additional, Aste, N., additional, Medina, G., additional, Exeni, I. E., additional, Gomez, G., additional, Pereira, D. A., additional, Granel, A. B., additional, Petkovic, I., additional, Pisoni, C., additional, Smichowski, A. M., additional, Sacnun, M., additional, Berbotto, G., additional, García, M., additional, Viola, M., additional, Bovea Castelblanco, G., additional, Saurit, V., additional, Kerzberg, E., additional, Larroude, M. S., additional, De La Sota, M. E., additional, Bertoli, A., additional, Diaz, M. P., additional, Castro, C., additional, Citera, G., additional, Casado, G., additional, Quintana, R., additional, Soriano, E., additional, Graf, C., additional, Pons-Estel, G., additional, and De la Vega, M., additional

Published
2023
Full Text
View/download PDF

14. POS1494 HOSPITALIZATIONS DUE TO INFECTIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS: CAUSES AND ASSOCIATED FACTORS

Author

Garcia, L., primary, Quintana, R., additional, Gobbi, C., additional, Alba, P., additional, Roverano, S., additional, Alvarez, A., additional, Graf, C., additional, Pisoni, C., additional, Spindler, A., additional, Gomez, C., additional, Figueredo, H. M., additional, Papasidero, S., additional, Paniego, R. H., additional, De la Vega, M., additional, Civit De Garignani, E. E., additional, Gonzalez Lucero, L., additional, Martire, V., additional, Águila Maldonado, R., additional, Gordon Dolimpio, S. A., additional, Micelli, M. L., additional, Nieto, R., additional, Rausch, G., additional, Góngora, V., additional, D’amico, M. A., additional, Dubinsky, D., additional, Orden, A. O., additional, Zacariaz, J., additional, Romero, J., additional, Pera, M. A., additional, Goñi, M. A., additional, Rillo, O., additional, Baez, R., additional, Arturi, V., additional, Gonzalez, A., additional, Vivero, F., additional, Bedoya, M. E., additional, Schmid, M., additional, Caputo, V., additional, Larroude, M. S., additional, Dominguez, N., additional, Pons-Estel, B., additional, Pons-Estel, G., additional, Bellomio, V. I., additional, and García, M., additional

Published
2023
Full Text
View/download PDF

15. AB1666 CLUSTER ANALYSIS TO IDENTIFY PATIENT GROUPS AND ASSESS THE PRESENCE OF ADVERSE EVENTS. REAL WORLD EVIDENCE FROM THE BIOBADASAR 3.0 REGISTRY

Author

Brigante, J. A., primary, Roberts, K., additional, Isnardi, C., additional, Gómez, G., additional, Haye, M., additional, García, M., additional, Gobbi, C., additional, Casado, G., additional, Holguín Arias, L. L., additional, Dapeña, J. M., additional, Papasidero, S., additional, Berbotto, G., additional, Viola, M., additional, Saurit, V., additional, Petkovic, I., additional, Bertoli, A., additional, Diaz, M. P., additional, Catay, E., additional, Exeni, I. E., additional, Pons-Estel, B., additional, Bovea Castelblanco, G., additional, De La Sota, M. E., additional, Larroude, M. S., additional, Pereira, D. A., additional, Granel, A. B., additional, Medina, G., additional, Pisoni, C., additional, Sacnun, M., additional, Velozo, E., additional, Aste, N., additional, Castro, C., additional, Kerzberg, E., additional, Savio, V., additional, Gamba, J., additional, Secco, A., additional, Citera, G., additional, Soriano, E., additional, Graf, C., additional, Pons-Estel, G., additional, and De la Vega, M., additional

Published
2023
Full Text
View/download PDF

16. AB1329 CLINICAL CHARACTERISTICS OF SARS-CoV-2 INFECTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN ARGENTINA: DATA FROM THE SAR-COVID NATIONAL REGISTRY

Author

Isnardi, C. A., primary, Roberts, K., additional, Tissera, Y., additional, Petkovic, I., additional, Berbotto, G., additional, Gobbi, C., additional, Tanten, R., additional, Cogo, A. K., additional, Asnal, C., additional, Baños, A. R., additional, Vivero, F., additional, Schmid, M., additional, Lazaro, M. A., additional, German, N., additional, Takashima, L., additional, Scafati, J., additional, Werner, M. L., additional, Casalla, L., additional, De la Vega Fernandez, S. S., additional, Castrillon Bustamante, D., additional, Rodriguez, F., additional, Moyano, S., additional, Martin, M. L., additional, Cosentino, V., additional, Herscovich, N., additional, Tralice, E. R., additional, Barbich, T., additional, Vasquez, D. L., additional, Buschiazzo, E., additional, Maid, P., additional, Ledesma, C., additional, Yohena, V., additional, Gómez, G., additional, Quintana, R., additional, and Pons-Estel, G., additional

Published
2023
Full Text
View/download PDF

17. OP0231 EVALUATION OF NON-CRITERIA MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME IN PATIENTS WITH SYSTEMIC LUPUSERYTHEMATOSUS ACCORDING TO ANTI-PHOSPHOLIPID ANTIBODY PROFILE

Author

Scafati, J., primary, Quintana, R., additional, Garcia, L., additional, Arizpe, F., additional, Gobbi, C., additional, Alba, P., additional, Roverano, S., additional, Alvarez, A., additional, Graf, C., additional, Pisoni, C., additional, Spindler, A., additional, Gomez, C., additional, Figueredo, H. M., additional, Papasidero, S., additional, Paniego, R. H., additional, De la Vega, M., additional, Civit De Garignani, E. E., additional, Gonzalez Lucero, L., additional, Águila Maldonado, R., additional, Micelli, M. L., additional, Nieto, R., additional, Rausch, G., additional, Góngora, V., additional, D’amico, M. A., additional, Dubinsky, D., additional, Orden, A. O., additional, Zacariaz, J., additional, Romero, J., additional, Pera, M. A., additional, Goñi, M. A., additional, Rillo, O., additional, Hojberg, N. G., additional, Vandale, J. M., additional, Allievi, A., additional, Paris, U. V., additional, Astesana, P., additional, Machado Escobar, M., additional, Sattler, M. E., additional, Arias, M., additional, Rojas Tessel, R., additional, Finucci, P., additional, Sarano, J., additional, Rodriguez, G., additional, Pons-Estel, B., additional, and García, M., additional

Published
2023
Full Text
View/download PDF

18. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

Author

Sharmin, S, Roos, I, Simpson-Yap, S, Malpes, C, Sanchez, MM, Ozakbas, S, Horakova, D, Havrdova, EK, Patti, F, Alroughani, R, Izquierdo, G, Eichau, S, Boz, C, Zakaria, M, Onofrj, M, Lugaresi, A, Weinstock-Guttman, B, Prat, A, Girard, M, Duquette, P, Terzi, M, Amato, MP, Karabudak, R, Grand'Maison, F, Khoury, SJ, Grammond, P, Lechner-Scott, J, Buzzard, K, Skibina, O, van der Walt, A, Butzkueven, H, Turkoglu, R, Altintas, A, Maimone, D, Kermode, A, Shalaby, N, Pesch, VV, Butler, E, Sidhom, Y, Gouider, R, Mrabet, S, Gerlach, O, Soysal, A, Barnett, M, Kuhle, J, Hughes, S, Sa, MJ, Hodgkinson, S, Oreja-Guevara, C, Ampapa, R, Petersen, T, Ramo-Tello, C, Spitaleri, D, McCombe, P, Taylor, B, Prevost, J, Foschi, M, Slee, M, McGuigan, C, Laureys, G, Hijfte, LV, de Gans, K, Solaro, C, Oh, J, Macdonell, R, Aguera-Morales, E, Singhal, B, Gray, O, Garber, J, Wijmeersch, BV, Simu, M, Castillo-Trivino, T, Sanchez-Menoyo, JL, Khurana, D, Al-Asmi, A, Al-Harbi, T, Deri, N, Fragoso, Y, Lalive, PH, Sinnige, LGF, Shaw, C, Shuey, N, Csepany, T, Sempere, AP, Moore, F, Decoo, D, Willekens, B, Gobbi, C, Massey, J, Hardy, T, Parratt, J, Kalincik, T, Sharmin, S, Roos, I, Simpson-Yap, S, Malpes, C, Sanchez, MM, Ozakbas, S, Horakova, D, Havrdova, EK, Patti, F, Alroughani, R, Izquierdo, G, Eichau, S, Boz, C, Zakaria, M, Onofrj, M, Lugaresi, A, Weinstock-Guttman, B, Prat, A, Girard, M, Duquette, P, Terzi, M, Amato, MP, Karabudak, R, Grand'Maison, F, Khoury, SJ, Grammond, P, Lechner-Scott, J, Buzzard, K, Skibina, O, van der Walt, A, Butzkueven, H, Turkoglu, R, Altintas, A, Maimone, D, Kermode, A, Shalaby, N, Pesch, VV, Butler, E, Sidhom, Y, Gouider, R, Mrabet, S, Gerlach, O, Soysal, A, Barnett, M, Kuhle, J, Hughes, S, Sa, MJ, Hodgkinson, S, Oreja-Guevara, C, Ampapa, R, Petersen, T, Ramo-Tello, C, Spitaleri, D, McCombe, P, Taylor, B, Prevost, J, Foschi, M, Slee, M, McGuigan, C, Laureys, G, Hijfte, LV, de Gans, K, Solaro, C, Oh, J, Macdonell, R, Aguera-Morales, E, Singhal, B, Gray, O, Garber, J, Wijmeersch, BV, Simu, M, Castillo-Trivino, T, Sanchez-Menoyo, JL, Khurana, D, Al-Asmi, A, Al-Harbi, T, Deri, N, Fragoso, Y, Lalive, PH, Sinnige, LGF, Shaw, C, Shuey, N, Csepany, T, Sempere, AP, Moore, F, Decoo, D, Willekens, B, Gobbi, C, Massey, J, Hardy, T, Parratt, J, and Kalincik, T

Abstract

Geographical variations in the incidence and prevalence of multiple sclerosis have been reported globally. Latitude as a surrogate for exposure to ultraviolet radiation but also other lifestyle and environmental factors are regarded as drivers of this variation. No previous studies evaluated geographical variation in the risk of secondary progressive multiple sclerosis, an advanced form of multiple sclerosis that is characterized by steady accrual of irreversible disability. We evaluated differences in the risk of secondary progressive multiple sclerosis in relation to latitude and country of residence, modified by high-to-moderate efficacy immunotherapy in a geographically diverse cohort of patients with relapsing-remitting multiple sclerosis. The study included relapsing-remitting multiple sclerosis patients from the global MSBase registry with at least one recorded assessment of disability. Secondary progressive multiple sclerosis was identified as per clinician diagnosis. Sensitivity analyses used the operationalized definition of secondary progressive multiple sclerosis and the Swedish decision tree algorithm. A proportional hazards model was used to estimate the cumulative risk of secondary progressive multiple sclerosis by country of residence (latitude), adjusted for sex, age at disease onset, time from onset to relapsing-remitting phase, disability (Multiple Sclerosis Severity Score) and relapse activity at study inclusion, national multiple sclerosis prevalence, government health expenditure, and proportion of time treated with high-to-moderate efficacy disease-modifying therapy. Geographical variation in time from relapsing-remitting phase to secondary progressive phase of multiple sclerosis was modelled through a proportional hazards model with spatially correlated frailties. We included 51 126 patients (72% female) from 27 countries. The median survival time from relapsing-remitting phase to secondary progressive multiple sclerosis among all patients wa

Published
2023

19. Clinical Impact and Polysomnographic Features of Sleep Disturbances in Multiple Sclerosis

Author

Sparasci, D., primary, Ferri, R., additional, Fanfulla, F., additional, Castelnovo, A., additional, Miano, S., additional, Tanioka, K., additional, Tachibana, N., additional, Heinzer, R., additional, Haba-Rubio, J., additional, Berger, M., additional, Riccitelli, G.C., additional, Disanto, G., additional, Zecca, C., additional, Gobbi, C., additional, and Manconi, M., additional

Published
2022
Full Text
View/download PDF

20. Foetal Allogeneic Intracerebroventricular Neural Stem Cell Transplantation in People with Secondary Progressive Multiple Sclerosis: A phase I dose-escalation clinical trial

Author

Leone, MA, primary, Gelati, M, additional, Profico, DC, additional, Conti, C, additional, Spera, C, additional, Muzi, G, additional, Grespi, V, additional, Bicchi, I, additional, Ricciolini, C, additional, Ferrari, D, additional, Zarrelli, M, additional, Amoruso, L, additional, Placentino, G, additional, Crociani, P, additional, Apollo, F, additional, Di Viesti, P, additional, Fogli, D, additional, Popolizio, T, additional, Colosimo, C, additional, Frondizi, D, additional, Stipa, G, additional, Tinella, E, additional, Ciampini, A, additional, Sabatini, S, additional, Paci, F, additional, Silveri, G, additional, Gobbi, C, additional, Pravatà, E, additional, Zecca, E, additional, Balzano, RF, additional, Kuhle, J, additional, Copetti, M, additional, Fontana, A, additional, Carella, M, additional, D’Aloisio, G, additional, Abate, L, additional, Ventura Carmenate, Y, additional, Pluchino, S, additional, Peruzzotti-Jametti, L, additional, and Vescovi, AL, additional

Published
2022
Full Text
View/download PDF

23. Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment

Author

Caporro M, Disanto G, Gobbi C, and Zecca C

Subjects
Medicine (General), R5-920
Abstract

Matteo Caporro, Giulio Disanto, Claudio Gobbi, Chiara Zecca Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano, Lugano, Switzerland Abstract: Glatiramer acetate, a synthetic amino acid polymer analog of myelin basic protein, is one of the first approved drugs for the treatment of relapsing–remitting multiple sclerosis. Several clinical trials have shown consistent and sustained efficacy of glatiramer acetate 20 mg subcutaneously daily in reducing relapses and new demyelinating lesions on magnetic resonance imaging in patients with relapsing–remitting multiple sclerosis, as well as comparable efficacy to high-dose interferon beta. Some preclinical and clinical data suggest a neuroprotective role for glatiramer acetate in multiple sclerosis. Glatiramer acetate is associated with a relatively favorable side-effect profile, and importantly this was confirmed also during long-term use. Glatiramer acetate is the only multiple sclerosis treatment compound that has gained the US Food and Drug Administration pregnancy category B. All these data support its current use as a first-line treatment option for patients with clinical isolated syndrome or relapsing–remitting multiple sclerosis. More recent data have shown that high-dose glatiramer acetate (ie, 40 mg) given three times weekly is effective, safe, and well tolerated in the treatment of relapsing–remitting multiple sclerosis, prompting the approval of this dosage in the US in early 2014.This high-dose, lower-frequency glatiramer acetate might represent a new, more convenient regimen of administration, and this might enhance patients’ adherence to the treatment, crucial for optimal disease control. Keywords: glatiramer acetate, disease modifying treatment, efficacy, safety

Published
2014

24. Imaging of neuralgic amyotrophy in the acute phase

Author

Ripellino, P., Arányi, Z., Alfen, N. van, Ventura, E., Peyer, A.K., Cianfoni, A., Gobbi, C., Pedrick, E., Sneag, D.B., Ripellino, P., Arányi, Z., Alfen, N. van, Ventura, E., Peyer, A.K., Cianfoni, A., Gobbi, C., Pedrick, E., and Sneag, D.B.

Abstract

Item does not contain fulltext, INTRODUCTION/AIMS: Hourglass-like constrictions (HGCs) occur in neuralgic amyotrophy (NA), but the earliest time at which they can be recognized by imaging is poorly understood. We aimed to determine the prevalence of abnormal imaging findings in the acute phase of NA. METHODS: Magnetic resonance neurography (MRN) and high-resolution ultrasound (US) examinations were performed at five sites. The investigation included 39 patients with acute NA who underwent imaging within 31 days of symptom onset. Correlation between imaging and electromyography (EMG) findings was measured. RESULTS: US was performed in 29 patients and MRN in 23; 16 patients underwent US only, 10 MRN only, and 13 had both. US and MRN showed nerve abnormalities within 1 mo from NA onset in 90% of patients. HGCs were found in 74% (29/39) of the patients: 4 within 1 wk, 8 within 2 wk, 5 within 3 wk, and 12 within 4 wk. The earliest HGC on US was found within 12 h, and on MRN within 3 days from symptom onset. MRN demonstrated a denervation edema pattern of affected muscles in 91% of the patients. The shortest time to observe an edema pattern on MRN was 8 days. EMG was performed in 30 patients and revealed fibrillation potentials in affected muscles in 22 (73%). A denervation edema pattern on MRN was significantly associated with the presence of HGCs both on MRN and US, and with fibrillation potentials on EMG. DISCUSSION: In the early phase of NA, US and MRN are useful diagnostic techniques for demonstrating nerve abnormalities.

Published
2022

25. A cross-country comparison of Covid-19 containment measures and their effects on the epidemic curves

Author

Cascini, Fidelia, Failla, Giovanna, Gobbi, C, Pallini, E, Hui, J, Wang, Lx, Villani, Leonardo, Quentin, W, Boccia, Stefania, Ricciardi, Walter, Cascini, F (ORCID:0000-0001-6499-0734), Failla, G, Villani, L (ORCID:0000-0001-9375-8731), Boccia, S (ORCID:0000-0002-1864-749X), Ricciardi, W (ORCID:0000-0002-5655-688X), Cascini, Fidelia, Failla, Giovanna, Gobbi, C, Pallini, E, Hui, J, Wang, Lx, Villani, Leonardo, Quentin, W, Boccia, Stefania, Ricciardi, Walter, Cascini, F (ORCID:0000-0001-6499-0734), Failla, G, Villani, L (ORCID:0000-0001-9375-8731), Boccia, S (ORCID:0000-0002-1864-749X), and Ricciardi, W (ORCID:0000-0002-5655-688X)

Abstract

Background European countries are still searching to eliminate or contain the Covid-19 pandemic. A variety of approaches have achieved different levels of success in limiting the spread of the disease early and preventing avoidable deaths. Governmental policy responses may explain these differences and this study aims to describe evidence about the effectiveness of containment measures throughout the course of the pandemic in five European countries (France, Germany, Italy, Spain and the UK). Methods The research approach adopted consisted of three steps: 1) Build a Containment Index (C.I.) that considers nine parameters to make an assessment on the strength of measures; 2) Develop dynamic epidemiological models for forecasting purposes; 3) Predict case numbers by assuming containment measures remain constant for a period of 30 days. Results Our analysis revealed that in the five European countries we compared, the use of different approaches definitively affected the effectiveness of containment measures for the Covid-19 pandemic. Conclusion The evidence found in our research can be useful to inform policy makers' decisions when deciding to introduce or relax containment measures and their timing, both during the current pandemic or in addressing possible future health crises.

Published
2022

26. Nonlesional Sources of Contrast Enhancement on Postgadolinium “Black-Blood” 3D T1-SPACE Images in Patients with Multiple Sclerosis

Author

Danieli, L., primary, Roccatagliata, L., additional, Distefano, D., additional, Prodi, E., additional, Riccitelli, G.C., additional, Diociasi, A., additional, Carmisciano, L., additional, Cianfoni, A., additional, Bartalena, T., additional, Kaelin-Lang, A., additional, Gobbi, C., additional, Zecca, C., additional, and Pravatà, E., additional

Published
2022
Full Text
View/download PDF

27. POS0655 SURVIVAL AND SAFETY OF BIOLOGICAL AND TARGETED SYNTHETIC THERAPIES AS REGARDS TO AGE GROUPS. BIOBADASAR 3.0 REGISTRY.

Author

Brigante, A., primary, Isnardi, C. A., additional, Gómez, G., additional, Quintana, R., additional, Haye, M., additional, Roberts, K., additional, García, M., additional, Gomez, G., additional, Gobbi, C., additional, Casado, G., additional, Rebak, J., additional, Dapeña, J. M., additional, Berbotto, G., additional, Viola, M., additional, Saurit, V., additional, Petkovic, I. E., additional, Bertoli, A., additional, Giorgis, P., additional, Diaz, M. P., additional, Catay, E., additional, Exeni, I. E., additional, Pons-Estel, B., additional, Paira, S., additional, Bovea Castelblanco, G., additional, De La Sota, M. E., additional, Larroude, M. S., additional, Pereira, D. A., additional, Granel, A. B., additional, Medina, G., additional, Pisoni, C., additional, Alvarez, A., additional, Aguero, S. E., additional, Fernandez, L., additional, Sacnun, M., additional, Soares de Souza, S., additional, Velozo, E., additional, Aste, N., additional, Castro, C., additional, Lazaro, A., additional, Kerzberg, E., additional, Gallardo, M. D. L. Á., additional, Savio, V., additional, Gamba, J., additional, Secco, A., additional, Citera, G., additional, Soriano, E., additional, Graf, C., additional, Pons-Estel, G., additional, and Delavega, M., additional

Published
2022
Full Text
View/download PDF

28. POS1199 IS PSORIATIC ARTHRITIS A RISK FACTOR FOR SEVERE COVID -19 INFECTION? DATA FROM THE ARGENTINIAN REGISTRY SAR-COVID

Author

Savio, V., primary, Maldini, C., additional, Alba, P., additional, Saurit, V., additional, Berbotto, G., additional, Pisoni, C., additional, Tissera, Y., additional, Nieto, R., additional, Maldonado, F., additional, Ornella, S., additional, Gobbi, C., additional, Baños, A. R., additional, Vivero, F., additional, Exeni, I. E., additional, Cusa, A., additional, Bellomio, V. I., additional, Perez Alamino, R., additional, Gomez, G., additional, Zelaya, D., additional, Risueño, F., additional, Quaglia, M. I., additional, Correa, M. D. L. A., additional, Rojas Tessel, R., additional, Delavega, M., additional, Lazaro, M. A., additional, Mercé, A. L., additional, Finucci, P., additional, Matellan, C. E., additional, Romeo, C., additional, Martire, V., additional, Moyano, S., additional, Martin, M. L., additional, Picco, E., additional, Goizueta, C., additional, Tralice, E. R., additional, Tamborenea, M. N., additional, Subils, G. C., additional, Gallo, R., additional, Pineda Vidal, S. I., additional, Velasco Zamora, J. L., additional, Lloves Schenone, N., additional, Cosentino, V., additional, Rodriguez, F., additional, Diaz, M. P., additional, Viola, M., additional, Mamani Ortega, M. L., additional, Buschiazzo, E., additional, Gómez, G., additional, Roberts, K., additional, Quintana, R., additional, Isnardi, C. A., additional, and Pons-Estel, G., additional

Published
2022
Full Text
View/download PDF

29. AB1101 PREVALENCE OF LONG COVID IN RHEUMATIC DISEASE PATIENTS: ANALYSIS OF SAR COVID REGISTRY

Author

Gonzalez Gomez, C. A., primary, Cosatti, M., additional, Castro Coello, V. V., additional, Haye, M., additional, Tissera, Y., additional, Reyes, A. A., additional, Albiero, J. A., additional, Ornella, S., additional, Alba, P., additional, Gobbi, C., additional, Gamba, M. J., additional, Exeni, I. E., additional, Cusa, A., additional, Gallino Yanzi, J., additional, Bellomio, V. I., additional, Gomez, G., additional, Zelaya, D., additional, Takashima, L., additional, Carlevaris, L., additional, Correa, M. D. L. A., additional, Rojas Tessel, R., additional, García, M., additional, German, N., additional, Mercé, A. L., additional, Bertoli, A., additional, Aguero, S. E., additional, Calvo, M. E., additional, Martire, V., additional, Mauri, M., additional, Martin, M. L., additional, Picco, E., additional, Castrillon Bustamante, D., additional, Ibañez Zurlo, L., additional, Tamborenea, M. N., additional, Subils, G. C., additional, Vasquez, D. L., additional, Soares de Souza, S., additional, Herscovich, N., additional, Raiti, L., additional, Cosentino, V., additional, Rodriguez, F., additional, Ledesma, C., additional, Diaz, M. P., additional, Mamani Ortega, M. L., additional, Castaño, M. S., additional, Gómez, G., additional, Roberts, K., additional, Quintana, R., additional, Isnardi, C. A., additional, Pons-Estel, G., additional, and Pisoni, C., additional

Published
2022
Full Text
View/download PDF

30. AB0511 SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY SCORE (SLE- DAS) VALIDATION IN ARGENTINIAN PATIENTS

Author

Pera, M., primary, Barbaglia, A. L., additional, Sueldo, H. R., additional, Gonzalez Lucero, L., additional, Corbalán, P. M., additional, Bertolaccini, M. C., additional, Espasa, G. V., additional, Leguizamón, M. L., additional, Galindo, L. M., additional, Ornella, S., additional, Garcia, L., additional, Scafati, J., additional, Cosentino, M., additional, Papasidero, S., additional, Dapeña, J. M., additional, Medina, M. A., additional, Scolnik, M., additional, Fernández-Ávila, D., additional, Pisoni, C., additional, Cosatti, M., additional, Rebak, J., additional, Sorrentino, L., additional, Magri, S. J., additional, Gobbi, C., additional, Matellan, C. E., additional, and Bellomio, V. I., additional

Published
2022
Full Text
View/download PDF

31. POS0707 POTENTIAL USE OF BELIMUMAB IN LUPUS PATIENTS FROM ARGENTINE COHORT ACCORDING DISEASE ACTIVITY STATE

Author

Quintana, R., primary, Garcia, L., additional, Alba, P., additional, Roverano, S., additional, Alvarez, A., additional, Graf, C., additional, Pisoni, C., additional, Spindler, A., additional, Gomez, C., additional, Figueredo, H. M., additional, Papasidero, S., additional, Paniego, R. H., additional, Delavega, M., additional, Civit De Garignani, E. E., additional, Gonzalez Lucero, L., additional, Martire, V., additional, Águila Maldonado, R., additional, Gordon, S., additional, Gobbi, C., additional, Nieto, R., additional, Rausch, G., additional, Góngora, V., additional, D’amico, M. A., additional, Dubinsky, D., additional, Orden, A. O., additional, Zacariaz, J., additional, Romero, J., additional, Pera, M. A., additional, Rillo, O., additional, Baez, R., additional, Arturi, V., additional, Gonzalez, A., additional, Vivero, F., additional, Schmid, M., additional, Caputo, V., additional, Larroude, M. S., additional, Gomez, G., additional, Rodriguez, G., additional, Marin, J., additional, Collado, M. V., additional, Jorfen, M., additional, Bedran, Z., additional, Sarano, J., additional, Zelaya, D., additional, Sacnun, M., additional, Finucci, P., additional, Rojas Tessel, R., additional, Sattler, M. E., additional, Machado Escobar, M., additional, Astesana, P., additional, Paris, U. V., additional, Allievi, A., additional, Vandale, J. M., additional, Pons-Estel, B., additional, Pons-Estel, G., additional, and García, M., additional

Published
2022
Full Text
View/download PDF

33. Life-threatening asthma attack during prolonged fingolimod treatment: case report

Author

Zecca C, Caporro M, Györik S, and Gobbi C

Subjects
Medicine (General), R5-920
Abstract

Chiara Zecca,1,* Matteo Caporro,1,* Sandor Györik,2 Claudio Gobbi11Neurocenter of Southern Switzerland, Department of Neurology, Ospedale Regionale di Lugano, Lugano, Switzerland; 2Department of Internal Medicine, Ospedale Regionale di Bellinzona, Bellinzona, Switzerland*These authors contributed equally to this workBackground: Fingolimod (FTY) mediates bronchoconstriction by interacting with sphingosine-1-phosphate receptors. The majority of the reported adverse respiratory events occur during the first weeks of treatment.Case presentation: A 49-year-old woman developed a life-threatening asthma attack after 6 months of continuous FTY treatment. The adverse event required prolonged hospitalization, and the patient recovered without sequelae after FTY interruption. A history of previous airway hyperreactivity and a concurrent viral respiratory infection possibly acted as predisposing factors.Conclusion: This first description of a severe, life-threatening asthma attack during prolonged FTY treatment suggests the need for long-term clinical surveillance, especially in patients with known predisposing factors.Keywords: multiple sclerosis, bronchial hyper-reactivity

Published
2014

35. Prognostic biomarkers in primary progressive multiple sclerosis: Validating and scrutinizing multimodal evoked potentials

Author

Hardmeier, M., Schlaeger, R., Lascano, A. M., Toffolet, L., Schindler, C., Gobbi, C., Lalive, P., Kuhle, J., Kappos, L., and Fuhr, P.

Subjects
Disability Evaluation, Multiple Sclerosis, Neurology, Physiology (medical), Disease Progression, Humans, Neurology (clinical), Multiple Sclerosis, Chronic Progressive, Prognosis, Evoked Potentials, Sensory Systems, Biomarkers
Abstract

OBJECTIVE: To validate the prognostic value of multimodal evoked potentials (mmEP) in primary progressive multiple sclerosis (PPMS) and to determine the most predictive EP-modalities. METHODS: Thirty-nine patients with PPMS (expanded disability status scale (EDSS): 2.0-6.5; mean clinical follow-up: 2.8 years) had visual (VEP), upper and lower limb somatosensory (SEP) and motor EP (MEP) at baseline. Quantitative EP-scores for single (qVEP, qSEP, qMEP) and combined modalities were correlated to EDSS and compared to previously published data of 21 PPMS patients. Predictors of EDSS-change were analyzed in pooled data by linear regression. RESULTS: Samples were comparable. Except qVEP, all EP-scores were correlated to EDSS at baseline (Rho: 0.45-0.69; p < 0.01) and follow-up (Rho: 0.59-0.80; p < 0.001). Combined EP-modalities significantly predicted EDSS-change (R(2)adj: 0.24), while EDSS and age did not. Tibial qSEP (R(2)adj: 0.22) and qMEP (R(2)adj: 0.26) were the best single modality predictors, outperformed by their combination (R(2)adj: 0.32). CONCLUSIONS: Quantitative EP-scores predict up to 32% of EDSS-change over three years. Modalities representing motor and long tract function carry the main prognostic information. SIGNIFICANCE: Replication of previous results corroborates the use of mmEP as a prognostic biomarker candidate in PPMS.

Published
2021

36. Improvement of interferon-beta related skin reactions after diluent halving: first experience of five patients

Author

Zecca C, Yawalkar N, and Gobbi C

Subjects
Medicine (General), R5-920
Abstract

Chiara Zecca,1 Nikhil Yawalkar,2 Claudio Gobbi11Neurocenter of Southern Switzerland, Lugano, 2Department of Dermatology, Bern University Hospital, Bern, SwitzerlandBackground: The spectrum of side effects related to interferon beta-1b (INF-1b) treatment may compromise long-term adherence.Methods: Five INF-1b-treated multiple sclerosis patients with poor skin tolerability and clinical stability were instructed to dissolve the established (250 µg) INF-1b dose in half (0.5 mL) the standard diluent (1.0 mL, 0.54% sodium chloride solution), and were followed for 9 months.Results: Halving the volume of the treatment diluent was associated with significant improvement of skin side effects profile in all patients. The improvement was sustained for 9 months.Conclusion: Halving the volume of the INF-1b diluent could represent a different strategy to optimize skin tolerability and adherence in some multiple sclerosis patients.Keywords: multiple sclerosis, interferon, treatment tolerability, side effects, skin reactions

Published
2012

40. Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Author

Wiendl, H., Gold, R., Berger, T., Derfuss, T., Linker, R., Mäurer, M., Aktas, O., Baum, K., Berghoff, M., Bittner, S., Chan, A., Czaplinski, A., Deisenhammer, F., Di Pauli, F., Du Pasquier, R., Enzinger, C., Fertl, E., Gass, A., Gehring, K., Gobbi, C., Goebels, N., Guger, M., Haghikia, A., Hartung, H.P., Heidenreich, F., Hoffmann, O., Kallmann, B., Kleinschnitz, C., Klotz, L., Leussink, V.I., Leutmezer, F., Limmroth, V., Lünemann, J.D., Lutterotti, A., Meuth, S.G., Meyding-Lamadé, U., Platten, M., Rieckmann, P., Schmidt, S., Tumani, H., Weber, F., Weber, M.S., Zettl, U.K., Ziemssen, T., Zipp, F., and ‘Multiple Sclerosis Therapy Consensus Group' (MSTCG)

Subjects
disease-modifying therapy, guideline, multiple sclerosis, treatment recommendation
Abstract

Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage. The approval of various disease-modifying therapies and our increased understanding of disease mechanisms and evolution in recent years have significantly changed the prognosis and course of the disease. This update of the Multiple Sclerosis Therapy Consensus Group treatment recommendation focuses on the most important recommendations for disease-modifying therapies of multiple sclerosis in 2021. Our recommendations are based on current scientific evidence and apply to those medications approved in wide parts of Europe, particularly German-speaking countries (Germany, Austria, and Switzerland).

Published
2021

41. The Multiple Sclerosis Data Alliance Catalogue: Enabling Web-Based Discovery of Metadata from Real-World Multiple Sclerosis Data Sources.

Author

Geys, L, Parciak, T, Pirmani, A, McBurney, R, Schmidt, H, Malbaša, T, Ziemssen, T, Bergmann, A, Rojas, JI, Cristiano, E, García-Merino, JA, Fernández, Ó, Kuhle, J, Gobbi, C, Delmas, A, Simpson-Yap, S, Nag, N, Yamout, B, Steinemann, N, Seeldrayers, P, Dubois, B, van der Mei, I, Stahmann, A, Drulovic, J, Pekmezovic, T, Brola, W, Tintore, M, Kalkers, N, Ivanov, R, Zakaria, M, Naseer, MA, Van Hecke, W, Grigoriadis, N, Boziki, M, Carra, A, Pawlak, MA, Dobson, R, Hellwig, K, Gallagher, A, Leocani, L, Dalla Costa, G, de Carvalho Sousa, NA, Van Wijmeersch, B, Peeters, LM, Geys, L, Parciak, T, Pirmani, A, McBurney, R, Schmidt, H, Malbaša, T, Ziemssen, T, Bergmann, A, Rojas, JI, Cristiano, E, García-Merino, JA, Fernández, Ó, Kuhle, J, Gobbi, C, Delmas, A, Simpson-Yap, S, Nag, N, Yamout, B, Steinemann, N, Seeldrayers, P, Dubois, B, van der Mei, I, Stahmann, A, Drulovic, J, Pekmezovic, T, Brola, W, Tintore, M, Kalkers, N, Ivanov, R, Zakaria, M, Naseer, MA, Van Hecke, W, Grigoriadis, N, Boziki, M, Carra, A, Pawlak, MA, Dobson, R, Hellwig, K, Gallagher, A, Leocani, L, Dalla Costa, G, de Carvalho Sousa, NA, Van Wijmeersch, B, and Peeters, LM

Abstract

BACKGROUND: One of the major objectives of the Multiple Sclerosis Data Alliance (MSDA) is to enable better discovery of multiple sclerosis (MS) real-world data (RWD). METHODS: We implemented the MSDA Catalogue, which is available worldwide. The current version of the MSDA Catalogue collects descriptive information on governance, purpose, inclusion criteria, procedures for data quality control, and how and which data are collected, including the use of e-health technologies and data on collection of COVID-19 variables. The current cataloguing procedure is performed in several manual steps, securing an effective catalogue. RESULTS: Herein we summarize the status of the MSDA Catalogue as of January 6, 2021. To date, 38 data sources across five continents are included in the MSDA Catalogue. These data sources differ in purpose, maturity, and variables collected, but this landscaping effort shows that there is substantial alignment on some domains. The MSDA Catalogue shows that personal data and basic disease data are the most collected categories of variables, whereas data on fatigue measurements and cognition scales are the least collected in MS registries/cohorts. CONCLUSIONS: The Web-based MSDA Catalogue provides strategic overview and allows authorized end users to browse metadata profiles of data cohorts and data sources. There are many existing and arising RWD sources in MS. Detailed cataloguing of MS RWD is a first and useful step toward reducing the time needed to discover MS RWD sets and promoting collaboration.

Published
2021

47. AB0214 SURVIVAL, EFFICACY AND SAFETY OF GOLIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS: DATA FROM AN ARGENTINEAN COHORT

Author

Isnardi, C. A., primary, Civit De Garignani, E. E., additional, García Ciccarelli, A., additional, Sanchez Alcover, J., additional, Garcia Salinas, R., additional, Magri, S., additional, Albiero, E., additional, Gobbi, C., additional, Velozo, E., additional, Soriano, E., additional, Brom, M., additional, Zacariaz, J., additional, Strusberg, I., additional, Baravalle, M., additional, Castaños, S., additional, Morales, L., additional, Paira, S., additional, Calvo, R., additional, Ortiz, A., additional, Perez Alamino, R., additional, Maldonado Ficco, H., additional, and Citera, G., additional

Published
2021
Full Text
View/download PDF

48. AB0342 OBSTETRIC AND THROMBOTIC ANTIPHOSPHOLIPID SYNDROME: ARE THEY DIFFERENT ENTITIES?

Author

Serrano Morales, R., primary, Nieto, R., additional, Porta, S., additional, Roberts, K., additional, Lema, L., additional, Maldini, C., additional, Tissera, Y., additional, Albiero, J. A., additional, Savio, V., additional, Goizueta, C., additional, Lobo, V., additional, Broll, A., additional, Cucchiaro, N., additional, ¨perez, S., additional, Izaguirre, P., additional, Estevez, A., additional, Abalo, A. I., additional, Etcheverry, M., additional, Bellomio, V. I., additional, Leguizamón, M. L., additional, Antoniol, N., additional, Perandones, C., additional, Pisoni, C., additional, De la Torre, M. L., additional, García, M., additional, Velloso, M. S., additional, Sacnun, M., additional, Gobbi, C., additional, Guaglione, D., additional, Vivero, F., additional, Saurit, V., additional, Benzaquen, N., additional, Nemman, V., additional, Remondino, G., additional, Machado Escobar, M., additional, Scolnik, M., additional, Danielsen, C., additional, Gomez, G., additional, Babini, A. M., additional, Brigante, A., additional, Luissi, A., additional, Castro Coello, V. V., additional, Sorrentino, L., additional, Berman, H., additional, Alba, P., additional, and Pons-Estel, G., additional

Published
2021
Full Text
View/download PDF

50. POS1186 EFFECT OF SOCIO-ECONOMIC STATUS AND EDUCATIONAL LEVEL ON COVID-19 OUTCOMES IN PATIENTS WITH RHEUMATIC DISEASES FROM ARGENTINA: DATA FROM THE SAR-COVID REGISTRY

Author

Sorrentino, L., primary, Rebak, J., additional, Maldonado, F., additional, Castro Coello, V. V., additional, Brigante, A., additional, Hamaui, A., additional, Dubinsky, D., additional, Baez, R., additional, Pisoni, C., additional, Gobbi, C., additional, Carlevaris, L., additional, Tanten, R., additional, Cogo, A. K., additional, Delavega, M., additional, Perez Alamino, R., additional, Lazaro, M. A., additional, Pera, M., additional, Pineda Vidal, S. I., additional, Calvo, M. E., additional, Guaglianone, D., additional, Alonso, C. G., additional, Guinsburg, M., additional, Retamozo, C., additional, Aeschlimann, C., additional, Quintana, R., additional, Roberts, K., additional, Isnardi, C. A., additional, and Pons Estel, G., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results